	US 11,911,473 B2
	Compositions and kits for omeprazole suspension
Zeus Pendon, Woburn, MA (US); and Steven Dinh, Burlington, MA (US)
Assigned to AZURITY PHARMACEUTICALS, INC., Woburn, MA (US)
Filed by Azurity Pharmaceuticals, Inc., Woburn, MA (US)
Filed on Mar. 30, 2023, as Appl. No. 18/128,344.
Application 18/128,344 is a continuation of application No. 17/576,496, filed on Jan. 14, 2022, granted, now 11,633,478.
Application 17/576,496 is a continuation of application No. PCT/US2020/042157, filed on Jul. 15, 2020.
Application PCT/US2020/042157 is a continuation in part of application No. 16/513,604, filed on Jul. 16, 2019, granted, now 10,751,333, issued on Aug. 25, 2020.
Prior Publication US 2023/0233682 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/10 (2017.01); A61K 9/10 (2006.01); A61K 31/4439 (2006.01); A61K 47/02 (2006.01); A61K 47/24 (2006.01); A61K 47/14 (2017.01); A61K 47/38 (2006.01)

CPC A61K 47/10 (2013.01) [A61K 9/10 (2013.01); A61K 31/4439 (2013.01); A61K 47/02 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/38 (2013.01)]

25 Claims

1. A method of treating a gastrointestinal disorder in a subject in need thereof, the method comprising:

administering a reconstituted proton pump inhibitor oral liquid formulation to the subject, wherein the reconstituted proton pump inhibitor oral liquid formulation comprises a proton pump inhibitor and a liquid diluent, and wherein the liquid diluent comprises:

a poloxamer, sodium carboxymethylcellulose (CMC), sodium bicarbonate, a buffering agent, simethicone emulsion, a preservative, a sweetener, water, and optionally one or more excipients selected from a flavoring agent and a coloring agent,

wherein the liquid diluent is stable for at least 30 days at 5±3° C.